Posts

Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502

Aclaris Therapeutics topical ATI-502

/in /by

Aclaris Therapeutics topical ATI-502

Mid-stage study underway for AclarisAclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, today announced the initiation of a Phase 2 open-label study of ATI-502, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-502 Topical), in patients with androgenetic alopecia (AGA), a condition characterized by a genetically determined male/female-pattern baldness.

This trial will evaluate the safety, tolerability and effect of ATI-502 Topical applied twice daily in 24 adult subjects (12 male, and 12 female) with androgenetic alopecia. This 30-week trial will be conducted at 3 investigational centers within the United States.

JAK signaling has been implicated in maintaining the hair cycle in its resting phase (telogen) in mice. Treatment of mouse telogen skin with topical JAK inhibitors prompts telogen follicles to enter the active growth phase (anagen). Hair loss disorders, such as AGA, in which the hair follicles are arrested in telogen phase, may be responsive to treatment with topical JAK inhibitors to promote their entry into anagen, and thus result in the initiation of hair growth.aclaris

“This trial is the first step in evaluating the potential clinical benefit of ATI-502 topical solution in treating patients with AGA, or male/female pattern baldness,” said Dr. Stuart Shanler, Chief Scientific Officer of Aclaris. “This is an important step forward in understanding the clinical utility of our JAK inhibitors in patients with AGA.”

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology.

Aclaris’ focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com

Source

Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502

Aclaris hair loss treatment

/in /by

Aclaris experimental hair loss treatment gets additional patent protection

A new drug candidate being developed by a Chester County biopharmaceutical company to treat hair loss disorders has received additional patent protection.

The U.S. Patent and Trademark Office issued the patent, which covers methods related to the use and administration of a certain janus kinase [JAK] inhibitor, to the trustees of Columbia University in New York City. Columbia has exclusively licensed the JAK inhibitor to Aclaris Therapeutics of Malvern, Pa., in connection with the company’s JAK drug development program for hair loss disorders.

JAK inhibitors are a type of medication designed to inhibit the activity of one or more of a specific family of enzymes tied to certain diseases.

U.S. patent number 9,895,301 covers the use of tofacitinib, a JAK inihibitor, for inducing hair growth and for treating hair loss disorders such as alopecia areata and androgenetic alopecia — otherwise known as male/female pattern hair loss.

“We are extremely pleased with the continued development of the patent portfolio we exclusively licensed from Columbia,” said Dr. Neal Walker, a dermatologist who serves as president and CEO of Aclaris. “The issuance of this patent is another step in the development of a robust patent portfolio relating to JAK inhibition and hair loss.”

Source